An Open Label, Single Dose, Mass Balance Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C-GSK2248761 200 mg, Administered as an Oral Suspension to Healthy Adult Subjects

Trial Profile

An Open Label, Single Dose, Mass Balance Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C-GSK2248761 200 mg, Administered as an Oral Suspension to Healthy Adult Subjects

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 02 Jul 2014

At a glance

  • Drugs Fosdevirine (Primary)
  • Indications HIV-1 infections
  • Focus Pharmacokinetics
  • Sponsors ViiV Healthcare
  • Most Recent Events

    • 25 Feb 2011 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 09 Feb 2011 The development program for IDX 899 has been placed on clinical hold by the FDA, according to an Idenix Pharmaceuticals media release.
    • 18 Jan 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top